{"title":"Valor del análisis de péptido natriurético en el diagnóstico y prevención de la insuficiencia cardíaca en poblaciones de alto riesgo.","authors":"Damien Gruson","doi":"10.1515/almed-2024-0122","DOIUrl":"https://doi.org/10.1515/almed-2024-0122","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"233-235"},"PeriodicalIF":1.1,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11381943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The value of natriuretic peptide testing for the diagnosis and prevention of heart failure in high-risk populations.","authors":"Damien Gruson","doi":"10.1515/almed-2024-0121","DOIUrl":"https://doi.org/10.1515/almed-2024-0121","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"231-232"},"PeriodicalIF":1.1,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11381084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sara Fernández-Landázuri, Ramón Baeza-Trinidad, Iván Bernardo González
{"title":"Impact of laboratory involvement in the characterization of B12 hypervitaminosis in clinical practice.","authors":"Sara Fernández-Landázuri, Ramón Baeza-Trinidad, Iván Bernardo González","doi":"10.1515/almed-2024-0098","DOIUrl":"https://doi.org/10.1515/almed-2024-0098","url":null,"abstract":"<p><strong>Objectives: </strong>Unexplained B12 hypervitaminosis (HB12) in asymptomatic patients leads to a cascade of medical consultations and diagnostic tests aimed at determining its etiology. The objective of this study was to assess the efficacy of the laboratory getting involved in the detection and elimination of immune complexes with vitamin B12 in clinical practice and its economic impact.</p><p><strong>Methods: </strong>A retrospective longitudinal study was undertaken to assess the laboratory strategy of detecting B12 macrovitamin (macro-B12) in patients with HB12 >1,000 pg/mL. The clinical characteristics of patients with HB12 referred to Internal Medicine (IM) in the pre- and post-implantation period of the new strategy were compared. Additionally, the healthcare costs of one-year follow-up were estimated.</p><p><strong>Results: </strong>The prevalences of HB12 in the pre- and post-implantation period were 3.9 % and 3 %, respectively. Macro-B12 explained 25 % of the HB12 cases initially detected. A 41 % reduction was observed in the number of patients with HB12 after the implantation of the new strategy, thereby resulting in a cost reduction of 5,000 €.</p><p><strong>Conclusions: </strong>The laboratory intervention for the detection of macro-B12 provides clear economic and clinical benefits in clinical practice.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"313-319"},"PeriodicalIF":1.1,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Managing laboratory test ordering: a challenge in the new laboratory medicine model.","authors":"María Salinas, Ruth Torreblanca, Eduardo Sanchez, Álvaro Blasco, Emilio Flores, Maite López-Garrigós","doi":"10.1515/almed-2024-0085","DOIUrl":"https://doi.org/10.1515/almed-2024-0085","url":null,"abstract":"<p><strong>Introduction: </strong>The role of Laboratory Medicine in patient care has evolved in the last decades. The same has occurred to the laboratory model, which has evolved from a traditional model where the laboratory is merely involved in clinical decision-making to a leading model where the laboratory is not only involved but also determines decision-making. The advent of new technologies and automation of processes have enabled laboratory professionals to focus on the first and last phase of the analytical process namely, test ordering and decision-making based on laboratory results. These phases are more error-prone than the analytical phase, and where action must be taken to improve the quality of patient care.</p><p><strong>Content: </strong>We share our experience in the design and establishment of laboratory test demand management interventions that facilitated diagnosis of occult disease, improved adherence to clinical guidelines, and optimized patient safety.</p><p><strong>Summary: </strong>A description is provided of key points in the management of laboratory test over/underutilization.</p><p><strong>Outlook: </strong>The objective of this review is to promote the involvement of laboratory professionals in the design and implementation of demand management interventions and in the development of the new Leader Laboratory model.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"236-247"},"PeriodicalIF":1.1,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11381944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María-José Castro-Castro, Isabel Cachón-Suárez, Andrea Maestre-Fernández, Rosa Navarro-Badal
{"title":"Interferencia del metamizol en la determinación de la concentración de creatinina sérica.","authors":"María-José Castro-Castro, Isabel Cachón-Suárez, Andrea Maestre-Fernández, Rosa Navarro-Badal","doi":"10.1515/almed-2024-0065","DOIUrl":"https://doi.org/10.1515/almed-2024-0065","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"296-300"},"PeriodicalIF":1.1,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"La gestión de la demanda de las pruebas: un reto en el nuevo modelo de medicina de laboratorio.","authors":"María Salinas, Ruth Torreblanca, Eduardo Sanchez, Álvaro Blasco, Emilio Flores, Maite López-Garrigós","doi":"10.1515/almed-2023-0146","DOIUrl":"https://doi.org/10.1515/almed-2023-0146","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"248-260"},"PeriodicalIF":1.1,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11381086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nuria Padilla Apuntate, Carmen G Puerto Cabeza, Alba Gallego Royo, Nuria Goñi Ros, Claudia Abadía Molina, Javier Acha Pérez, Pilar Calmarza
{"title":"Effects of antidiabetic drugs on bone metabolism.","authors":"Nuria Padilla Apuntate, Carmen G Puerto Cabeza, Alba Gallego Royo, Nuria Goñi Ros, Claudia Abadía Molina, Javier Acha Pérez, Pilar Calmarza","doi":"10.1515/almed-2024-0038","DOIUrl":"https://doi.org/10.1515/almed-2024-0038","url":null,"abstract":"<p><strong>Objectives: </strong>The prevalence of diabetes mellitus type 2 (DMT2) is increasing exponentially worldwide. DMT2 patients have been found to be at a higher risk for bone fractures than the healthy population. Hence, improving our understanding of the impact of antidiabetic drugs on bone metabolism is crucial.</p><p><strong>Methods: </strong>A descriptive, retrospective study involving 106 patients receiving six groups of antidiabetic drugs: insulin; dipeptidylpeptidase four inhibitors (DPP4i); glucagon-like peptide type 1 receptor agonists (GLP1ra); sulfonylureas; sodium-glucose cotransporter two inhibitors (SGLT2i); and pioglitazone, in which osteocalcin (OC), bone alkaline phosphatase (BAP) and C-terminal telopeptide of collagen type 1 or beta-crosslaps (β-CTx) were determined.</p><p><strong>Results: </strong>β-CTx concentrations were higher in the patients treated with pioglitazone, as compared to patients treated with DPP4i (p=0.035), SGLT2i (p=0.020) or GLP1ra (p<0.001). The lowest β-CTx concentrations were observed in the patients treated with GLP1ra.</p><p><strong>Conclusions: </strong>Bone remodeling is influenced by the type of antidiabetic drug administered to DMT2 patients. In our study, the patients who received pioglitazone showed higher β-CTx concentrations, as compared to patients treated with other types of antidiabetic drugs. This finding highlights the convenience of avoiding these drugs, especially in postmenopausal women with DMT2. GLP1ra drugs were associated with the lowest β-CTx concentrations, which suggests that these agents could exert beneficial effects on bone metabolism.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 1","pages":"85-89"},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11019883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carmen Ricós, Carmen Perich, Sandra Bullich, Montserrat Ventura, Berta Piqueras, Mariona Panadés, Pilar Fernández-Calle
{"title":"Compliance to specifications in an external quality assurance program: did new biological variation estimates of the European Federation of Laboratory Medicine (EFLM) affect the quality of laboratory results?","authors":"Carmen Ricós, Carmen Perich, Sandra Bullich, Montserrat Ventura, Berta Piqueras, Mariona Panadés, Pilar Fernández-Calle","doi":"10.1515/almed-2023-0155","DOIUrl":"https://doi.org/10.1515/almed-2023-0155","url":null,"abstract":"<p><strong>Objectives: </strong>The results of external quality assurance schemes are evaluated against specifications generally based on biological variation (BV) data. This study was carried out to determine whether new BV values affected the level of compliance to specifications. Our secondary objective was to identify the conditions that would be compromised as a result of poor analytical performance in disease associated markers.</p><p><strong>Methods: </strong>This study was based on the results of the SEQC<sup>ML</sup> External Quality Assurance scheme for the 2015-2022 period. Deviation of the individual result from the target value was estimated. Additionally, we calculated the percentage of results that met the pre-established specification.</p><p><strong>Results: </strong>In 97 of the 133 analytes, the level of compliance was maintained in 80-90 % of the results obtained in the two study periods. In 23 analytes, the level of compliance ranged from 51 to 79 % in the two study periods. In ALT, AST and sodium, the level of compliance was ≤50 % of the results obtained in the first study period, with sodium being the only analyte that maintained this poor level of compliance in the second study period.</p><p><strong>Conclusions: </strong>The level of compliance to specifications remained independent from the specification used (SEQC<sup>ML</sup> or EFLM) for the majority of the analytes. The results for sodium ion were below the target value, which may lead to misdiagnosis of hyponatremia. Non-compensated alkaline picrate methods overestimate creatinine, which may produce false information suggestive of kidney failure.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 4","pages":"379-386"},"PeriodicalIF":0.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alba M Rodrigo Valero, Oscar Quintela Jorge, Begoña Bravo Serrano, Sara Ayuso Tejedor
{"title":"Optimization of a rapid method for screening drugs in blood by liquid chromatography tandem mass spectrometry.","authors":"Alba M Rodrigo Valero, Oscar Quintela Jorge, Begoña Bravo Serrano, Sara Ayuso Tejedor","doi":"10.1515/almed-2023-0154","DOIUrl":"10.1515/almed-2023-0154","url":null,"abstract":"<p><strong>Objectives: </strong>In the recent years, liquid chromatography with tandem mass spectrometry has gained popularity in laboratories. This technique has a higher specificity, detects different analytes from a single specimen, measures analytes in distinct matrices, and substantially reduce analytical interference, with respect to immunoassay. The processing and preparation of biological samples are crucial in chromatography. Interferences in blood testing are usually caused by the presence of phospholipids and proteins. The main objective of this study was to improve analytical processes for drug screening by LC-MS/MS using a novel blood sample preparation method based on protein precipitation and removal of phospholipids.</p><p><strong>Methods: </strong>An evaluation was performed of a new method for the preparation of blood samples based on protein precipitation and removal of phospholipids by LC-Q-q-LIT.</p><p><strong>Results: </strong>Limit of detection, limit of quantification and measurement range were determined for 56 molecules. The results of 11 cases were compared with those obtained using standard blood collection methods and instruments.</p><p><strong>Conclusions: </strong>The novel blood preparation and testing method based on LC-Q-q-LIT, a more sensitive technique, has demonstrated to yield comparable results to traditional methods. In addition, this new technique reduces turnaround time and costs.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 4","pages":"365-371"},"PeriodicalIF":1.1,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cristina de Paz Poves, Clara Barneo-Caragol, Ana Isabel Cillero Sánchez, Lucía Jimenez Mendiguchia, Covadonga Quirós Caso, María Moreno Rodríguez, Francisco J. López González, Mᵃ Belén Prieto García
{"title":"Evaluation of Diasorin Liaison<sup>®</sup> calprotectin fecal assay adapted for pleural effusion","authors":"Cristina de Paz Poves, Clara Barneo-Caragol, Ana Isabel Cillero Sánchez, Lucía Jimenez Mendiguchia, Covadonga Quirós Caso, María Moreno Rodríguez, Francisco J. López González, Mᵃ Belén Prieto García","doi":"10.1515/almed-2023-0106","DOIUrl":"https://doi.org/10.1515/almed-2023-0106","url":null,"abstract":"Abstract Objectives Calprotectin (CP) is a calcium and zinc binding protein that is widely measured on faecal samples but its determination in other biological fluids might be of interest. The aim of this work was to validate the measurement of CP in pleural fluid by chemiluminescence. Methods LIAISON ® XL, a fully automated chemiluminescence analyzer, was used for CP quantification on pleural fluid. A validation protocol was designed using both quality control materials provided by the manufacturer and pools of pleural fluid samples. Stability, imprecision, bias, linearity, detection capability and carry over effect were evaluated. Results CP was stable on pleural fluid at least one week, under refrigerated conditions, and four weeks at −80 °C. The observed intra- and inter-day imprecision was between 2.2 and 6.49 %, with a negative bias under 5.51 %. The linearity of the method was verified up to 2,000 ng/mL. The LoQ for the assay was 48.52 ng/mL. A statistically significant carry-over effect was observed after measuring CP concentrations above the upper limit of linearity, but given the observed magnitude, a clinically relevant impact should not be expected. Conclusions Diasorin Liaison ® calprotectin assay allows reliable measurement of CP in pleural fluid.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"7 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136229438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}